Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals, Inc. (KALV), sold 14,226 shares at $8.23 ($117K) on 2023-11-20, disclosed to the SEC on 2023-11-21.
Seasonal sale ($117k) by Chief Development Officer — this insider has traded KALV in November in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.23 | 7,113 | $59K | 50.0% |
| 2 | $8.23 | 7,113 | $59K | 50.0% |
| Total | $8.23 avg | 14,226 | $117K | 100% |
| Filing → |
| KALV | SELL | 2026-05-26 | $63K | — | Filing → |
| KALV | SELL | 2026-05-19 | $30K | — | Filing → |
| KALV | SELL | 2026-02-24 | $68K | — | Filing → |